ロード中...
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well understood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-opti...
保存先:
| 出版年: | Chin J Cancer |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124233/ https://ncbi.nlm.nih.gov/pubmed/27887628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0162-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|